ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1582308
This article is part of the Research TopicThe Insights of Multi-Omics into the Microenvironment After Tumor Metastasis: A Paradigm Shift in Molecular Targeting Modeling and Immunotherapy for Advanced Cancer PatientsView all 7 articles
The Impact of Sarcopenia on Prognosis and Fruquintinib Efficacy in Advanced Colorectal Cancer: A Retrospective and Mendelian Randomization Analysis
Provisionally accepted
Wang Yao1,2
Meilu Du1
Qi Shi1Yufei Tang1
Song Gao1
Susu Han1Haotian Wen1Tingting Zhu1
Chao Wang2*
Fenggang Hou1
Xiaoling Yin1- 1Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
- 2Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Reportedly, sarcopenia is associated with prognosis in advanced colorectal cancer (CRC) patients and can lead to reduced efficacy of targeted therapy.However, studies on the relationship between sarcopenia and the prognosis (or efficacy) of advanced CRC patients receiving fruquintinib targeted therapy remain scarce. Therefore, we conducted a comprehensive assessment of the relationship between nutritional status, inflammation, immune function, and sarcopenia. We also investigated whether sarcopenia affects the therapeutic efficacy of fruquintinib targeted therapy.In this retrospective study, sarcopenia and several markers of nutritional status and immune function were assessed in advanced CRC patients with fruquintinib therapy at the hospital. We used drug target mendelian randomization (MR) analysis to investigate the effect of fruquintinib on sarcopenia.Results: Advanced CRC patients with sarcopenia had a poorer prognosis compared to those without sarcopenia. Furthermore, sarcopenia showed a strong correlation with various markers of nutritional status, immune function indicators, inflammation markers, quality of life scores, and the prognostic nutrition index. MR studies suggest that the spleen tyrosine kinase (SYK) gene is a key factor in the occurrence of sarcopenia associated with the use of fruquintinib.Sarcopenia could be a prognostic factor in patients with advanced CRC receiving fruquintinib targeted therapy.
Keywords: Sarcopenia, Nutritional assessment, Advanced colorectal cancer, fruquintinib, Mendelian randomization study
Received: 24 Feb 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 Yao, Du, Shi, Tang, Gao, Han, Wen, Zhu, Wang, Hou and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chao Wang, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.